Cargando…
Immunotherapy with Subcutaneous Injection of Immunomodulatory Agent (OK-432) Elicits Durable Response in Locally Advanced or Relapsed Cervical Cancer
Immunotherapy (IT) has been studied as a new and alternative treatment option for locally advanced, persistent, recurrent, or relapsed cervical cancer in an effort to extend the life and possibly cure patients with advanced stage disease. Targeted immune checkpoint inhibitors augment anticancer immu...
Autores principales: | Alas, Quenny Michelle Dyan A., Lin, Cheng-Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515755/ https://www.ncbi.nlm.nih.gov/pubmed/31143629 http://dx.doi.org/10.4103/GMIT.GMIT_1_19 |
Ejemplares similares
-
OK-432 Treatment of Ranula Intruding into the Cervical Region
por: Ohta, Nobuo, et al.
Publicado: (2022) -
The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients
por: Gochi, A, et al.
Publicado: (2001) -
Response to OK-432 sclerotherapy in the treatment of cervical lymphangioma with submucosal extension to the airway()
por: Manzini, Michelle, et al.
Publicado: (2016) -
Percutaneous Treatment of Renal Cysts with OK-432 Sclerosis
por: Choi, Young Deuk, et al.
Publicado: (2007) -
CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
por: Zhang, Juan, et al.
Publicado: (2022)